Skip to main content

Remote Job Finders (RJF)

Despite Novo’s Robust Oral Wegovy Launch, Access Remains a Challenge for Obesity Drugs

This year’s catalysts in the space include a near-term FDA decision on Eli Lilly’s oral challenger to the new Wegovy pill. Looking further ahead, Novo Nordisk is expecting more clinical data for next-gen weight loss asset CagriSema, which recently lost a head-to-head battle with Lilly’s Zepbound.

UCB Investing $2B To Build Manufacturing Facility in Georgia

The Belgian drugmaker plans to hire about 330 people at a facility that will use advanced manufacturing technologies including AI, robotics and automation to meet rising demand for key products. This will be UCB’s first biologics manufacturing facility in the U.S.
Scroll to top